Conditions: Alzheimer Disease Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 36
Healthy volunteers: yes

Brief summary:
This study is being done for the following reasons:

To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It will also look at how safe and tolerable the study drug is when given to healthy participants in higher doses.

This research study is being conducted in three groups, referred to as Groups (Cohorts) A, B, or C.

Group A will enroll participants with Alzheimer's disease while Groups B and C will enroll healthy participants.

For Group A or B, participation in this research study could last up to 34 days. For Group C, participation could last up to 60 days.

Detailed description:

Arms:
arm 1: Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721. arm 2: Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule). arm 3: Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721. arm 4: Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule). arm 5: Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721. arm 6: Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).

Interventions: intervention 1: LY2886721 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: